2 ms·
It's not remotely close to $100m Editas acquired Cpf1 exclusivity for just $16 million upfront [1], in the form of cash plus a note. Intellia and Crispr Therap
by adventured 10y ago
It's not remotely close to $100m
Editas acquired Cpf1 exclusivity for just $16 million upfront [1], in the form of cash plus a note. Intellia and Crispr Therapeutics, as two examples, will be able to license Cas9 from Broad for their various programs for a lot closer to $20m upfront plus royalties (so far as their therapy paths don't directly collide with Editas).
http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-newsArticle&ID=2230504 http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-n...